Representative experiment out of three.(B)Comparison of PCs generated from CD27+ B-cells either activated with CD40L-expressing fibroblasts or cultured in the presence of CpG2006. we compared the differentiation of CD27+ B-cells isolated from either the tonsils or peripheral blood and stimulated with either CD40L-expressing fibroblasts or a TLR9 ligand, CpG oligodeoxynucleotide (CpG ODN). We observed that CpG ODN mainly induced CD27+ B-cell differentiation into CD20+CD38+CD138 PBs and CD20+CD38+CD138 PCs, which appear much like tonsil PCs. Removal of CpG ODN during differentiation induced a decrease in the CD20+ plasmablastic populace, and, conversely, activation of CD40L-induced pre-plasmablasts with CpG ODN increased the population of CD20+CD38+ PBs. Analysis of Ig secretion showed that CpG ODN induced increased IgM secretion compared to CD40L. PCs from patients with multiple myeloma, the malignant counterpart of bone marrow PCs, rarely express CD20. We show that CpG ODN did not induce or increase CD20 in nine IgG or IgA myeloma cell lines. These data strongly suggest that CpG ODN mainly targets CD27+ IgM+ B-cells. Keywords:plasma cells, survival, CpG, CD20 == Introduction == Plasma cells (PCs) are terminally differentiated B-cells (Shapiro-Shelef and Calame,2005; De Vos et al.,2006; Moser et al.,2006; Radbruch et al.,2006). Memory B-cells are activated in secondary immune organs and differentiate into plasmablasts (PBs), which migrate to inflamed tissues, lamina propria, and bone marrow, where they differentiate into PCs (Arpin et al.,1997). Long-lived PCs that are the source of protective antibodies are mainly located within the bone marrow. PCs are found not only within bone marrow but are also located within secondary immune organs such as the spleen, lymph nodes, and tonsils. PCs in all organs exhibit a shared phenotype, but some differences can be observed. For example, tonsil PCs are CD20+ and CD138+/, in contrast to BM PCs that are CD20 but CD138++ (Pellat-Deceunynck et al.,1994; Medina et al.,2002; SKLB1002 Robillard et al.,2005). During B-cell differentiation into PCs, CD20 expression is usually lost at the plasmablastic stage and CD138 upregulation occurs at the PC stage (Jego et al.,2001).In vivo, expansions of non-malignant polyclonal PBs and PCs are transiently SKLB1002 observed in patients with IL-6 producing tumors or in the context of acute infections (Jego et al.,1999). These PBs and PCs never express CD20 (Jego et al.,1999). PCs from tonsil have been considered to be immature PCs, which can leave the tonsil to migrate to the bone marrow. However, phenotypic studies of cytoplasmic Ig+ (cIg+) cells in the blood during a secondary immune response have shown that cIg+ cells have a phenotype common for PBs, CD20CD138, making it unlikely that tonsil PCs are the precursors to BM PCs or peripheral PBs (Medina et al.,2002; Odendahl et al.,2005; Robillard et al.,2005). Based on phenotype, the tonsil PCs appear to be different from other types of PCs or PBs. In vitro, PBs and PCs have been mainly obtained from memory B-cells activated by CD40L (Arpin et al.,1995; Jego et al.,2001). In this culture system, the PBs and PCs obtained by no means expressed CD20. Microbial products activate B-cells, which express a wide range of toll-like receptors (TLRs). Indeed, B-cells express TLR9 and are strongly activated by TLR9 ligand, CpG oligodeoxynucleotides (CpG ODN). Bernasconi et al. (2002) have reported that CpG ODN induce the proliferation and differentiation of CD27+ B-cells into PCs and that CpG ODN, in contrast to CD40L, strongly stimulate IgM+ B-cells. Thus, we wondered whether the activation of CD27+ B-cells by two very different culture systems (CD40L or CpG ODN) would generate PBs and PCs with comparable or different features. Our data show that CpG ODN, in contrast to CD40L, promote the era of Compact disc20+ Personal computers. == Components and Strategies == == Antibodies and reagents == Anti-CD20-FITC, anti-CD38-APC, and IgG1-APC control had been bought from BD Biosciences (Le Pont de Claix, France). Anti-CD45-FITC, anti-CD138-PE, IgG1-FITC control, and IgG1-PE control had been bought from Beckman Coulter (Roissy, France). Blocking anti-CD40L mAb was bought from Alexis (Coger, Paris, France). The recombinant human being cytokines IL2, IL10, and IL15 had been from R&D (Minneapolis, SKLB1002 MN, USA). The TLR9 ligand, CpG phosphorothioated ODN (5-0TCGTCGTTTTGTCGTTTTGTCGTT-30, CpG2006), was bought from InvivoGen (NORTH PARK, CA, USA). Antibodies against Bim (Abs) and actin (mAb) had been bought from Millipore (Merck Serono, Lyon, France), anti-Mcl-1 Abs and anti-caspase 3 mAb had been bought from Santa Cruz Biotechnology (Tebu-Bio, Le Perray en Yvelines, France), anti-Bcl-2 mAb was bought from Dako (Trappes, Rabbit Polyclonal to AML1 France), anti-p27 and anti-PCNA mAbs had been bought from BD Pharmingen (BD Biosciences, Le Pont de Claix, France), anti-p18 mAb was bought from Cell Signaling Technology (Ozyme, Saint-Quentin en Yvelines, France), anti-Bcl-xL.